Trial Profile

Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR Positive Cancers by Positron Emission Tomography (PET)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nimotuzumab (Primary)
Indications Cancer; Colorectal cancer; Lung cancer
Focus Diagnostic use

Most Recent Events

05 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
05 Jan 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2026.
18 May 2022 Planned End Date changed from 1 Aug 2022 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com